Cathay Capital Invests in OriGene Technologies

May 4, 2020

Cathay Capital Private Equity, the first self-made global private equity firm and a leader in cross-border investment in Europe, China and the United States, today announced that it has successfully made an investment in OriGene Technologies, a life science company producing biotechnology products for the research and medical markets. This investment will be made through the Sino French Fund for SMEs (Sino French Fund), an investment vehicle designed to support the development of French and Chinese small and medium enterprises internationally. This operation was undertaken alongside co-investors IDG Capital Partners and Mérieux Développement.

Established in 1996 by experienced medical professionals, OriGene is a leading life science technology company which develops and markets products for research laboratories, diagnostic companies, clinics and hospitals. Its business line mainly focuses on the manufacture of biological reagents (including cDNA, proteins, and antibodies) providing technological solutions for the markets of in-vitro diagnosis and immunohistochemistry. With a footprint already spanning mainland China and the USA, OriGene has expanded its offer to the clinical diagnostic reagent market over the past ten years through both organic growth and strategic acquisitions, and is now a leading company within major healthcare markets with a solid product base and a strong tradition of innovation.

As the leader of this consortium of investors, Cathay Capital will fully leverage its resources across Europe, China and North America, in order to help OriGene deepen its cooperation with global laboratories and grow its product sales in Europer, and therefore support the company’s ambition to become a fully-integrated global player in pathology diagnostics and antibodies.

Weiwu He, Founder and CEO of OriGene, said: “With a unique cross-border investment model and truly global presence, Cathay Capital is the ideal partner to support the next phase of our growth alongside its co-investors, who bring solid expertise within the in-vitro diagnosis field. We would like to thank Cathay Capital, who will be able to help us in deploying our growth strategy, and we look forward to working closely with this new investment consortium.”

Mingpo Cai, President of Cathay Capital Private Equity, commented: “Cathay Capital has developed a strong expertise within the health sector, a market segment which enjoys a promising growth outlook in our view. OriGene is a unique life sciences company with significant growth potential. With our partners, we will provide our strategic resources on a worldwide level as well as our vast experience in the sector to help boost demand for its products in Europe and to create new partnerships with international research organizations. We will offer continued support to the company with our co-investors in order to maintain the quality of its products, by selecting the best technologies and raw materials for antibody- and protein-based solutions. The ultimate objective is to enable the company to successfully undertake a new stage in its development and growth to become a recognized world leader in biotechnology.”


About Cathay Capital Private Equity

Cathay Capital Private Equity, founded by Mingpo Cai and Edouard Moinet in Paris in 2006, is the leading global middle-market, private equity firm created by Entrepreneurs for Entrepreneurs. As an expert in creating value through cross-border investments in Europe, China and North America, Cathay Capital is fully dedicated to helping its portfolio company management teams focus on growth and succeed beyond their home base. Cathay’s unique platform on three continents – and offices currently located in Shanghai, Beijing, New York and Paris – as well as its multicultural team including thirty investment professionals, enables the firm to locally accelerate cross-border growth strategies through its broad local ecosystems.

As of December 31, 2014, Cathay Capital had invested in 36 companies and over 900 million Euros under management.

Press contacts

Yoann Besse – [email protected] – Tel : +33 (0)1 53 32 78 89 / +33 (0)6 63 03 84 91

Dominic Riding – [email protected] – Tel : +33 (0)1 53 32 84 74 / +33 (0)7 60 90 89 13